B. Braun’s Commitment to Home Infusion Therapy on Display at NHIA 2017

BETHLEHEM, Pa., May 17, 2017 -- With a rich history of bringing new products and services  to the home infusion market, B. Braun Medical Inc. will showcase its latest technology and innovation at this year’s National Home Infusion Association (NHIA) Conference & Exposition at the Hilton Orlando from May 22-25.

Among B. Braun’s latest advancements at booth #317 will be the APEX^® Compounding System, which represents the latest advancement in macro and micro compounding technology. It was specifically designed to address the immediate needs of critically ill patients – from neonates to adults - while also meeting the critical needs of pharmacists.

Pharmacists now have a choice in using a compounder that is able to compound both macro and micronutrients. APEX incorporates a large user interface, 26-lead preassembled sets and dual-drive filling technology with automated delivery as low as 0.2 mL.  

APEX works with its own proprietary clinical decision support software – TPN Manager – which incorporates Trissel’s™ Ca/P Safety Check Software. When technicians scan the barcode on the label generated by TPN Manager, the order information is automatically programmed into the APEX compounder without the need for transcription. This function is designed to help reduce manual programming and transcription errors and expedite patient care.     

B. Braun also will introduce a new iPad-based educational resource for those using the company’s Easypump^® ST/LT Elastomeric Infusion Pump System. Through text, photos and videos, the Home Infusion Therapy App helps infusion therapy nurses explain the features of the pump system and teach patients how to safely use the Easypump in the comfort of their own homes.

NHIA attendees who visit B. Braun’s booth #317 can also learn about the company’s extensive portfolio of infusion products and programs, which also include:

• OnGuard^® CSTD — a closed system transfer device designed for the safe handling of hazardous drugs in any care setting with simple-to-use components. OnGuard meets the NIOSH definition of a CSTD and is the only CSTD tested with chemotherapy drugs for vapor containment.
• Readyfor800.com — an online educational resource informing healthcare professionals about the new hazardous drug safety standard, USP <800>. The site defines USP <800> in detail and provides expert insight and recommendations into achieving compliance and maintaining the safest environment possible when handling hazardous drugs.

About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap^® and CAPS^®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise^® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

Contact:         
Jason Ford
B. Braun Medical Inc.
610.997.4722 
[email protected]